AGP Executive Report
Last update: 2 hours agoMedical Breakthrough: A Phase 2 trial presented at the 2026 Alzheimer’s Association conference reports that a cannabis-based oral mix of THC (2mg) and CBD (100mg) twice daily improved agitation in late-stage dementia—about 84% improved after two weeks, rising to nearly 90% by 12 weeks. Regulatory/Market Watch: Florida hemp businesses are bracing for a planned federal ban on THC products starting Nov. 12, arguing it could wipe out most existing hemp-derived items under a “total THC” standard. Enforcement (Drugs, not CBD): Nigeria’s NDLEA says it seized 1.63 million tramadol pills hidden in two trailers headed to Kano and arrested multiple suspects, while also intercepting synthetic cannabis (“Canadian Loud”) from Canada. Compliance/Industry Risk: Michigan regulators allege a cannabis processor illegally transported products to Massachusetts before surrendering its license, raising more cross-state compliance concerns. Public Safety: A UK shop lost its licence after trading standards found fake goods and illegal vapes, plus unlicensed ED products—another reminder that “CBD-adjacent” retail can get swept into broader crackdowns.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
